Header
For Healthcare Professionals

India: Rental safety

Why Glyxambi_Patient CRM_Banner_2x

Renal safety

Renal evidence with Empagliflozin and Linagliptin1,2

16-9-copy-3@2x
16-9-copy-3@2x
16-9-copy-2@2x
16-9-copy-2@2x

Glyxambi® is not indicated in the treatment of CKD.
* Exploratory endpoint in the EMPA-REG OUTCOME® trial.
# Prespecified microvascular endpoint in the CARMELINA® trial.
† Exploratory outcome in the CARMELINA® trial.
FDC: Fixed-dose combination. EMPA: Empagliflozin. LINA: Linagliptin. HR: Hazard ratio.
RRR: Relative risk reduction. UACR: Urine albumin-to-creatinine ratio. Cl: Confidence interval.
CKD: Chronic kidney disease.

 

References:
  1. Wanner C, et al. N Engl J Med. 2016;375:323-334.
  2. Rosenstock J, et al. JAMA. 2019;321(1):6 9-79.